Emergent BioSolutions (EBS) Misses Q2 EPS by 1c
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $6.85 +4.58%
Revenue Growth %: -45.6%
Financial Fact:
Other income (expense), net: -234K
Today's EPS Names:
OCCI, ALZN, ASPU, More
Revenue Growth %: -45.6%
Financial Fact:
Other income (expense), net: -234K
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q2 EPS of ($0.18), $0.01 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $101.5 million versus the consensus estimate of $111.2 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- FactSet acquires BCC Group to expand real-time market data platform
- KT&G approves KRW 360 billion share buyback and retirement plan
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
